title: Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease.
abstract: OBJECTIVE
  To evaluate the efficacy of solifenacin succinate in Parkinson's disease (PD) patients suffering from overactive bladder (OAB).
  
  
  BACKGROUND
  Urinary dysfunction is a commonly encountered non-motor feature in PD that significantly impacts patient quality of life.
  
  
  METHODS
  This was a double-blind, randomized, placebo-controlled, 3-site study with an open label extension phase to determine the efficacy of solifenacin succinate in idiopathic PD patients with OAB. Patients were randomized to receive solifenacin succinate 5-10 mg daily or placebo for 12 weeks followed by an 8-week open label extension. The primary outcome measure was the change in the mean number of micturitions per 24 h period. Secondary outcome measures included the change in the mean number of urinary incontinence episodes and the mean number of nocturia episodes.
  
  
  RESULTS
  Twenty-three patients were randomized in the study. There was no significant improvement in the primary outcome measure in the double-blind phase, but there was an improvement in the number of micturitions per 24 h period in the solifenacin succinate group compared to placebo at a mean dose of 6 mg/day (p = 0.01). In the open label phase, the mean number of urinary incontinence episodes per 24 h period decreased (p = 0.03), as did the number of nocturia episodes per 24 h period (p = 0.01). Adverse events included constipation and xerostomia, which resolved after treatment was discontinued.
  
  
  CONCLUSIONS
  In this pilot trial, solifenacin succinate treatment led to an improvement in urinary incontinence, despite persistence in other OAB symptoms.
authors: Department of Neurology, University of South Florida, Tampa, FL, USA. Electronic address: tzesiewi@health.usf.edu.
authors: Theresa A
authors: TA
authors: Zesiewicz
authors: Department of Neurology, Atlanta VA Medical Center and Emory University, Atlanta, GA, USA.
authors: Marian
authors: M
authors: Evatt
authors: Department of Medicine, Atlanta VA Medical Center and Emory University, Atlanta, GA, USA.
authors: Camille P
authors: CP
authors: Vaughan
authors: Department of Neurology, University of South Florida, Tampa, FL, USA.
authors: Israt
authors: I
authors: Jahan
authors: Department of Neurology, University of Miami, Miami, FL, USA.
authors: Carlos
authors: C
authors: Singer
authors: Department of Urology, University of South Florida, Tampa, FL, USA.
authors: Raul
authors: R
authors: Ordorica
authors: Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX, USA.
authors: Jason L
authors: JL
authors: Salemi
authors: Department of Neurology, University of South Florida, Tampa, FL, USA.
authors: Jessica D
authors: JD
authors: Shaw
authors: Department of Epidemiology, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA, USA.
authors: Kelly L
authors: KL
authors: Sullivan
mesh_terms: D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D010865:Pilot Projects; D000069464:Solifenacin Succinate / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D014549:Urinary Incontinence / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D064804:Urological Agents / Q000627:therapeutic use*
chemical_list: D064804:Urological Agents; D000069464:Solifenacin Succinate
keywords: Non-motor symptoms; Overactive bladder; Parkinson's disease; Solifenacin succinate; Urinary incontinence